Navigation Links
Inflammation in Medical Technology

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

... has become a global standard measurement of inflammation and destruction in those joints. For these ... clinical condition. ** Synovitis: inflammation of the synovial membrane lining joints Osteitis: inflammation of the bone Safety Results ...

Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome

... is referred to as "metabolic syndrome." Low level inflammation and oxidative stress are the mechanistic ... The Cardax drug reduces systemic inflammation and oxidative stress while localizing in the ... safe, small molecule compounds that impact inflammation driven by mitochondrial oxidative stress. The ...

VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease

... which are important mediators of the inflammation believed to be involved in the development and ... Inc. "VIA-2291 specifically targets the inflammation in atherosclerotic plaque that is thought to ... as demonstrated by reduction in carotid plaque inflammation and non-calcified coronary plaque volume. We ...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... in the inflammatory process, relieves both inflammation of the joints and certain systemic effects of RA. ... systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

... in the inflammatory process, relieves both inflammation of the joints and certain systemic effects of RA. ... systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, ...

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis

... healthy joint tissue, thereby causing swelling, inflammation and damage of joints, as well as systemic inflammation and damage of other tissues. About MDX-1100 ... assessment and the assessment of colon mucosal inflammation ascertained by endoscopy. Ulcerative colitis ...

Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

... coronary events with Near-term Cardiovascular inflammation Suppression), a clinical trial designed to ... inhibition of sPLA2 effectively suppressed inflammation following the index event and was further ... compounds inhibit novel¿ upstream steps in the inflammation cascade and have the potential to address a ...

Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

... that is deemed to be safe and able to suppress inflammation by inhibiting sPLA2 provides an opportunity for ... for cardiovascular and sickle cell disease where inflammation plays a fundamental role in patient outcomes. We ... compounds inhibit novel¿ upstream steps in the inflammation cascade and have the potential to address a ...

New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits

... benefits of these medications as well." inflammation and Asthma Treatments Asthma is a chronic respiratory disease caused by inflammation and swelling of the airways and constriction of ... use of inhaled corticosteroids to reduce airway inflammation and mucus production. Statins are ...

Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain

... of motion, 94.1% got relief from arthritis and inflammation and a full 100% had relief from muscle pain and ... swelling in the joints; and third, by decreasing inflammation in the affected tissues. Together, ... arthritis "hot spots," while the capsules fight inflammation at its source for whole-body relief from pain. ...

Laser Burn Injuries in One Eye Can Disrupt Protective Immune Privilege in Both Eyes, Study Finds

... Immune privilege protects the eye without the inflammation of the body's normal immune response, which can ... without the full-blown immune response that uses inflammation to violently reject foreign tissue or invaders. While inflammation in other parts of the body is a useful battle ...

Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis

... esophagus. This eosinophil infiltration leads to inflammation of the esophagus and is believed to cause the ... profile in those diseases. It works by decreasing inflammation in the treated area. Meritage Pharma's ... pediatric eosinophilic esophagitis, an allergic inflammation of the gastrointestinal tract and is currently in ...

Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease

... Research Uncovers New Link Between inflammation & Alzheimer's Disease SARASOTA, ... its researchers have uncovered a new link between inflammation and Alzheimer's disease and have identified a ... at the Roskamp Institute has revealed that inflammation can lead to the production of more amyloid, and ...

ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%

... primary efficacy endpoint of absence of ocular inflammation 15 days following surgery. In addition, Xibrom ... strong trends in both the absence of ocular inflammation and pain but did not meet statistical ... of patients with complete absence of ocular inflammation was assessed on Day 15 post surgery. ...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

... in the inflammatory process, relieves both inflammation of the joints and certain systemic effects of RA. ... systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, ...

VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease

... of leukotrienes, that are important mediators of inflammation believed to be involved in the development ... VIA-2291's effect on atherosclerotic vascular inflammation in 50 patients scheduled for elective CEA. CEA is ... direct evaluation of VIA- 2291's effect on inflammation by analyzing plaque removed from the carotid ...

Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented

... Administration in June 2008 for the treatment of inflammation and pain associated with ocular surgery. (Logo: ... is anterior uveitis, associated primarily with inflammation of the iris. If left untreated, uveitis can ... corticosteroid approved for the treatment of inflammation and pain associated with ocular surgery. ...

Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)

... indicated for the treatment of inflammation and pain associated with ocular surgery; it was ... be used effectively four times a day to reduce inflammation in patients with moderate to severe uveitis," ... in reducing the symptoms of anterior ocular inflammation (pain/ocular discomfort, photophobia, blurred ...

Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain

... corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery. To ... and only steroid with an approval for both inflammation and pain, it is the first innovation in the ... Durezol for the management of postoperative inflammation in which treatment was initiated one day prior to ...

Interleukin Genetics Wins International Award for Outstanding Research Published in the Journal, Nutrition

... IL1 Heart Health Supplement) could lower inflammation in individuals who tested positive ... who are genetically predisposed to over-produce inflammation and are at an increased risk for an early ... botanical supplement, was developed to reduce inflammation in those individuals who are genetic ...

Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302

... cataract surgery and on pain, discomfort and inflammation following the procedure. OMS302 is added ... and commercializing products focused on inflammation and disorders of the central nervous system. ... pipeline of pre-clinical programs targeting inflammation and central nervous system disorders. For more ...

New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis

... damage. Additionally, new therapies that target inflammation are being developed. Today the Within our Reach ... on how the central nervous system can control inflammation in RA. The group identified a new pathway that allows the spinal cord and brain to decrease joint inflammation and joint destruction. Now that this pathway is ...

VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial

... is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease ... provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid ... of inflammation to measure reduction of inflammation in treated patients. The Phase 2 program of ...

Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis

... a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, ... About Noninfectious Uveitis Uveitis is an inflammation of the internal structures of the eye. Uveitis ... therapeutic products for autoimmune diseases, inflammation and pain. Cerimon believes these new ...

VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial

... is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease ... provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid ... of leukotrienes (important mediators of inflammation involved in the development and progression ...

Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis

... assessment and the assessment of colon mucosal inflammation ascertained by endoscopy. Patients in the Phase ... disease of the colon and is characterized by inflammation and ulceration of the lining of the colon. ... and damage of joints, as well as systemic inflammation and damage of other tissues. About Medarex ...

Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics' Heart Health Test

... 1B genetic patterns predict life-long tendency to inflammation and related cardiovascular event risk ... UK, commented, "It is now well recognized that inflammation is an underlying factor in many diseases ... products to prevent or treat diseases of inflammation and other genetic variations, our ability ...

Tart Cherries May Reduce Inflammation, Lower Risk for Type 2 Diabetes & Heart Disease

... annual meeting. As science continues to reveal inflammation may be a marker for many chronic diseases, ... percent of the diet, reduced two known markers of inflammation by up to 50 percent. TNF-alpha was reduced by 50 ... rats and 38 percent in the lean rats. While inflammation is a normal process the body uses to fight ...

ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation

... of ocular pain and mean reduction of markers of inflammation (inflammatory cells and flare). In addition, the ... compound for the treatment of ocular inflammation and pain. Xibrom, approved in 2005, is the first and only FDA-approved twice-daily NSAID for inflammation and reduction of pain following cataract surgery. ...

International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet

... and C-reactive protein (CRP), a marker of inflammation due to RA, compared with patients receiving ... involved in the inflammatory process, may reduce inflammation of the joints and relieve certain systemic ... systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. ...

VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial

... is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease ... provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid ... will also measure standard serum biomarkers of inflammation to measure reduction of inflammation in treated ...

Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial

... heart disease with associated hyperlipidemia and inflammation who are currently not achieving adequate ... C-Reactive Protein (CRP), a recognized marker of inflammation and possible cardiovascular risk. Decreases in ... compounds inhibit novel upstream steps in the inflammation cascade and have the potential to address a ...

VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation

... to measure VIA-2291's ability to reduce vascular inflammation in treated patients. The company also provided a ... is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease ... intended to provide new visibility to the role of inflammation in cardiovascular disease and the potential of ...

NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020

... COPD is a respiratory disease caused by chronic inflammation of the lungs and bronchi and represents ... NicOx is targeting the therapeutic areas of inflammation and cardio-metabolic disease. Resources are ... on the very good safety profile and effect on inflammation seen in our recently completed Phase 2 study of ...

ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting

... primary efficacy endpoint of absence of ocular inflammation 15 days following surgery and the secondary ... at Day 1 and complete absence of ocular inflammation was assessed on Day 15. Sunday, November 11th; ... compound for the treatment of ocular inflammation and pain. Xibrom is the first and ...

VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis

... of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). The data were presented at the inflammation and Adhesion Molecules II session at the American ... Atherosclerosis is the result of chronic inflammation and the buildup of plaque in arterial blood ...

Sirion Therapeutics Announces Positive Phase III Results for Difluprednate

... the steroid's potential to rapidly resolve inflammation in the eye following ocular surgery. "We are ... or equal to 10) or higher the day after surgery. inflammation was measured by the number of cells in the ... measured the proportion of subjects whose inflammation reached Grade 0 at Day 8. Both difluprednate ...

VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome

... for VIA-2291, its lead compound. VIA-2291 targets inflammation in the blood vessel wall, an underlying cause of ... the impact of VIA-2291 on reducing vascular inflammation in treated patients. The Company plans to enroll ... in the study will include reduction in plaque inflammation as measured with FDG-PET, as well as assessment ...

Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial

... C-Reactive Protein (CRP), a recognized marker of inflammation and cardiovascular risk. Decreases in these ... disease with associated hyperlipidemia and inflammation who are currently not achieving adequate ... compounds inhibit novel upstream steps in the inflammation cascade and have the potential to address a ...

Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease

... Lipoprotein Cholesterol "LDL-C") and systemic inflammation (as measured by levels of C-Reactive Protein ... heart disease, with associated hyperlipidemia and inflammation who are currently not achieving ... compounds inhibit novel upstream steps in the inflammation cascade and have the potential to address a ...
Other Contents
(Date:9/23/2014)... majority of drugs used to treat asthma today are the ... are urgently needed to treat this chronic respiratory disease, which ... to wheeze, cough, and find it difficult at best to ... is tough: asthma is a patient-specific disease, so what works ... animal models traditionally used to test new drug candidates often ...
(Date:9/23/2014)... , 23 de septiembre de 2014 ... del Sistema 1290 Infinity II LC, el ... Infinity en su portafolio de cromatografía líquida. ... y directores de laboratorio que alcancen nuevos ... facilidad de uso y capacidad de integración ...
(Date:9/23/2014)... Most organisms, including humans, have parasitic DNA fragments called ... genetic instructions in the process. And that phenomenon can ... at the University of Rochester now report that the ... age when a multi-function protein stops keeping them in ... , In a study published today in Nature ...
Breaking Biology News(10 mins):Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 3A multi-function protein is key to stopping genomic parasites from 'jumping' 2
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows all ... it can be treated. , A medically retired Army ... His platoon sustained multiple attacks resulting in five casualties. ... combat-related PTSD and honorably discharged from the Army. , ... distanced myself from my friends and family,” recalled O’Farrell, ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 ... for providing better care, not more ... choices. A new report suggests that,s the direction ... the IMS Institute for Healthcare Informatics in Parsippany, N.J., identifies ... the delivery of health care and use of medicines over ...
(Date:9/23/2014)... September 23, 2014 What information ... The National Quality Forum (NQF) released a report ... ), and an infographic ( http://bit.ly/1tX3lzA ) resulting ... of healthcare, how patients define affordability, and what ... get the best possible healthcare at the lowest ...
(Date:9/23/2014)... CORVALLIS, Ore. A recent Oregon survey about an ... into the daily routine of elementary school students found ... students and teachers, and offered clear advantages for overly ... was developed and produced by the Healthy Youth Program ... and is available nationally. , Brain Breaks leads children ...
(Date:9/23/2014)... 2014 Trevera provides multiple lines ... are Oracle Managed Services , Oracle Solutions ... versions of Oracle E-Business Databases and Applications, ... Trevera has announced a significant enhancement to its ... with their software technology management, project management, governance, ...
Breaking Medicine News(10 mins):Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Report Identifies Game Changers for U.S. Health Care 2Health News:Report Identifies Game Changers for U.S. Health Care 3Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Trevera, Inc adds Management Support to Services 2Health News:Trevera, Inc adds Management Support to Services 3
Other TagsOther Tags